Dianthus Therapeutics, Inc. /DE/ Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Dianthus Therapeutics, Inc. /DE/ (DNTH) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value of $466.69 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue · last filed 2026-08-04
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $466.69M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $384.14M.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $127.55M.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $126.22M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value as first filed |
|---|---|---|
| 2026-06-30 | $466.69M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $384.14M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $127.55M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $126.22M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $15.47M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $14.01M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $24.87M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $49.03M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $42.78M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $51.07M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $3.18M 10-K · filed 2025-03-11 | |
| 2023-09-30 | $7.76M 10-Q · filed 2023-11-09 | |
| 2022-12-31 | $0.00 10-K · filed 2024-03-21 | |
| 2021-12-31 | $194.00K 8-K · filed 2023-12-21 | $0.00 10-K · filed 2023-03-23 |
| 2020-12-31 | $2.14M 10-K · filed 2022-03-08 | |
| 2019-12-31 | $29.63M 10-K · filed 2021-03-03 | |
| 2018-12-31 | $526.00K 10-K · filed 2020-03-03 | |
| 2017-12-31 | $1.79M 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |